Crispr Therapeutics shares tumble after significant earnings miss
Michele Lau, the Executive Vice President and Chief Legal Officer at McKesson Corp (NYSE:MCK), recently sold a portion of her holdings in the company. The stock has shown impressive momentum, delivering a 21.34% return over the past year and currently trades near its 52-week high of $637.51. According to a filing with the Securities and Exchange Commission, Lau sold 312 shares of McKesson’s common stock on February 25, 2025, at a price of $605 per share. This transaction, executed under a pre-established trading plan, amounted to a total value of $188,760. InvestingPro analysis shows the company currently trades at $621.42, with 12+ additional exclusive insights available to subscribers.
Following the sale, Lau retains direct ownership of 2,808 shares. Additionally, she holds 138.5181 shares indirectly through the McKesson Corporation 401(k) Retirement Savings Plan. McKesson, with a market capitalization of $77.88 billion, remains a prominent player in the Healthcare Providers & Services industry.
In other recent news, McKesson Corporation reported third-quarter earnings and revenue that did not meet analyst expectations, with adjusted earnings per share at $8.03, below the consensus of $8.27. Revenue reached $95.29 billion, an 18% year-over-year increase, but still fell short of the projected $95.77 billion. Despite the earnings miss, McKesson raised its fiscal 2025 adjusted EPS guidance to a range of $32.55-$32.95, with the midpoint slightly above analyst expectations. The U.S. Pharmaceutical (TADAWUL:2070) segment, McKesson’s largest, experienced a 19% revenue growth, driven by increased prescription volumes and oncology platform growth.
Additionally, McKesson announced plans to acquire a controlling interest in PRISM Vision Holdings LLC for $850 million and Florida Cancer Specialists & Research Institute for $2.5 billion. These acquisitions are part of McKesson’s strategy to expand its specialty services. S&P Global Ratings revised McKesson’s outlook to positive from stable, affirming its ’BBB+’ rating, based on anticipated growth in the U.S. pharmaceutical and prescription technology segments. Citi analyst Daniel Grosslight raised the stock price target to $685, maintaining a Buy rating, citing strong performance in the pharmaceutical segment despite challenges in the Med-Surg division. McKesson’s management remains optimistic, highlighting robust revenue growth and operational strength across the enterprise.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.